Nmdae for schizophrenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Jan 2018: Trial started, NCT04745143
  2. 9 Feb 2021: Trial registered, NCT04745143

The trials

NCT04745143: Monotherapy of an NMDA Enhancer for Schizophrenia

State
Under way
Phase
Phase 2
People
80 planned
Started
1 Jan 2018
Primary completion
Sep 2027
Arms
NMDAE
Results
None posted
  1. 1 Jan 2018: Trial started
  2. 9 Feb 2021: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.